...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run.
【24h】

Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run.

机译：22961 EORTC试用版的质量保证。通过LHRH类似物与放射治疗对局部晚期前列腺癌进行治疗的荷尔蒙辅助治疗最佳组合的III期研究：假人。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: The EORTC trial 22961, opened in 1997, was designed to investigate the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer. A dummy run was established to assess centre compliance to the radiotherapy protocol. MATERIALS AND METHODS: Medical and anatomical data obtained from 37 CT slices (5mm thickness) of an eligible patient were sent to 19 participating centres, which were asked to complete a questionnaire according to their practice and plan a theoretical radiotherapy treatment. The Planning Target Volume 1 (PTV1) should include prostate, seminal vesicles, internal iliac lymph nodes and inferior part of common iliac lymph nodes (extended pelvic fields). Centres which usually irradiate with small pelvic fields (N0 patients), were allowed to include the prostate, seminal vesicles and internal iliac lymph nodes plus a safety margin of 2cm. For the Planning Target Volume 2 (PTV2), a safety margin of 1.5 to 2cm should be around the prostate and seminal vesicles. Checks included patient positioning, treatment simulation, target volume definition, treatment set-up and clinical controls during treatment. RESULTS: Eleven institutions with actual 81% of patients' accrual in the protocol have responded. All centres used a supine treatment position and positioning lasers for the set-up, while 73 and 45% of the centres performed cystograms and used rectal contrast, respectively. Among the participating centres, 45% and 55% used blocks and MLC, respectively, to treat patients. Extended pelvic fields in terms of PTV1 were used by 63% of the centres. The remaining centres treated a small PTV1 with a 10-20mm margin around to CTV1. All centres defined PTV2 according to protocol guidelines. Doses to PTV1 and PTV2 were correctly prescribed. It was difficult to assess the treated volumes due to a lack of standardisation in DVH calculations. CONCLUSION: In general, centres participating in the dummy run adhered to the guidelines. The dummy run enhances the reliability of the conclusions of the trial.
机译：目的：EORTC试验22961于1997年开始，旨在研究LHRH类似物和放射疗法对激素辅助治疗对局部晚期前列腺癌的治疗的最佳组合。建立了一个虚拟运行以评估中心对放射治疗方案的依从性。材料与方法：将符合条件的患者的37层CT切片（5毫米厚）获得的医学和解剖学数据发送至19个参与中心，要求这些中心根据他们的实践填写调查表并计划理论放疗治疗。规划目标第1卷（PTV1）应包括前列腺，精囊，internal内淋巴结和common总下淋巴结的下部（盆腔扩大）。通常用小骨盆区域照射的中心（N0例患者）被允许包括前列腺，精囊和and内淋巴结，安全范围为2cm。对于计划目标体积2（PTV2），前列腺和精囊周围应有1.5到2厘米的安全裕度。检查包括患者定位，治疗模拟，目标量定义，治疗设置以及治疗期间的临床对照。结果：协议中有11个机构实际占患者应得比例的11％。所有中心都使用仰卧位和定位激光进行设置，而分别有73％和45％的中心进行了膀胱造影和直肠造影。在参与研究的中心中，分别有45％和55％的患者使用区块和MLC来治疗患者。 63％的中心使用了根据PTV1扩展的骨盆视野。其余中心处理了一个小的PTV1，其边缘距CTV1约10-20mm。所有中心均根据协议指南定义了PTV2。正确规定了PTV1和PTV2的剂量。由于DVH计算缺乏标准化，因此难以评估治疗量。结论：一般而言，参加模拟跑的中心都遵守指南。虚拟运行可增强试验结论的可靠性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号